James Hu named associate director of Sarcoma Program at Cedars-Sinai Cancer

Oncofertility coverage mandates expand to 21 states and DC as political momentum builds
Gaps persist as patients face harrowing decisions and huge copays

The nagging pain in Mia Sandino’s right knee set in in September 2018, and throughout her freshman year at the University of Washington, she tried to ignore it. “I was being a very naive and invincible-feeling 19-year-old,” Sandino told The Cancer Letter. “I didn’t put two and two together that this area of the knee that...

November 21, 2025

Vol.51 No.43

By Claire Marie Porter and Sara Willa Ernst

Clinical Roundup

Targeted drug could benefit pediatric and young adult patients with invasive soft tissue cancer

A collaborative research team, led by scientists at VCU Massey Comprehensive Cancer Center and Huntsman Cancer Institute at the University of Utah, has identified a targeted drug that could effectively treat an aggressive soft tissue cancer that occurs most often in pediatric and young adult patients.

November 21, 2025

Vol.51 No.43

In Brief

Eytan Ruppin named deputy director of Translational Research Institute at Cedars-Sinai

Eytan Ruppin, a data scientist who works with AI-based methods for predicting individual patients’ response to cancer therapies, has joined Cedars-Sinai Cancer as deputy director of the Translational Research Institute. He will also serve as director of Integrative Data Sciences in the Division of Surgical Research.

October 31, 2025

Vol.51 No.40

Clinical Roundup

Ozekibart improves PFS in chondrosarcoma, registrational phase II trial shows

Positive topline results from the registrational ChonDRAgon study investigating ozekibart (INBRX-109) as a single agent versus placebo in patients with advanced or metastatic, unresectable chondrosarcoma were recently reported.

October 31, 2025

Vol.51 No.40

Clinical Roundup

Drugs approved for pain also reduce bone cancer growth, Hopkins-led pre-clinical study finds

Federally funded research in mice showed that neurons regulate osteosarcoma progression, suggesting that inhibiting nerve signaling might improve patient outcomes.

October 31, 2025

Vol.51 No.40

Clinical Roundup

GammaTile delivers superior tumor control vs. standard-of-care for newly diagnosed operable brain metastases

GammaTile showed superiority in the primary endpoint of the study. Patients who received GammaTile lived longer without tumor regrowth, reducing the risk of either tumor recurrence or death by 50% reduction compared to standard of care, according to interim results from the ROADS clinical trial, which evaluated GammaTile versus standard of care in patients with operable, newly diagnosed brain metastases.

October 24, 2025

Vol.51 No.39

James Hu named associate director of Sarcoma Program at Cedars-Sinai Cancer

YOU MAY BE INTERESTED IN

Oncofertility coverage mandates expand to 21 states and DC as political momentum builds
Gaps persist as patients face harrowing decisions and huge copays

Targeted drug could benefit pediatric and young adult patients with invasive soft tissue cancer

Eytan Ruppin named deputy director of Translational Research Institute at Cedars-Sinai

Ozekibart improves PFS in chondrosarcoma, registrational phase II trial shows

Drugs approved for pain also reduce bone cancer growth, Hopkins-led pre-clinical study finds

GammaTile delivers superior tumor control vs. standard-of-care for newly diagnosed operable brain metastases

Renew today!

Subscriber content

Never miss an issue!

Login

James Hu named associate director of Sarcoma Program at Cedars-Sinai Cancer

YOU MAY BE INTERESTED IN

Oncofertility coverage mandates expand to 21 states and DC as political momentum buildsGaps persist as patients face harrowing decisions and huge copays

Targeted drug could benefit pediatric and young adult patients with invasive soft tissue cancer

Eytan Ruppin named deputy director of Translational Research Institute at Cedars-Sinai

Ozekibart improves PFS in chondrosarcoma, registrational phase II trial shows

Drugs approved for pain also reduce bone cancer growth, Hopkins-led pre-clinical study finds

GammaTile delivers superior tumor control vs. standard-of-care for newly diagnosed operable brain metastases

Never miss an issue!

Login

Oncofertility coverage mandates expand to 21 states and DC as political momentum builds
Gaps persist as patients face harrowing decisions and huge copays